Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gentian Diagnostics ASOSL:GENT 77 5-Year Yield-on-Cost % is 1.51 as of Jul. 28, 2026, which is 104% above its 10-year median of 0.74. GuruFocus rates OSL:GENT with a GF Score™ of 77/100 and a GF Value™ of kr59.21 (Significantly Undervalued). Among 323 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 66.25% on this metric.
Gentian Diagnostics AS's yield on cost for the quarter that ended in Jun. 2026 was 1.51.
The historical rank and industry rank for Gentian Diagnostics AS's 5-Year Yield-on-Cost % or its related term are showing as below:
OSL:GENT'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.63 Med: 0.74 Max: 1.62
Current: 1.51
During the past 13 years, Gentian Diagnostics AS's highest Yield on Cost was 1.62. The lowest was 0.63. And the median was 0.74.
OSL:GENT's 5-Year Yield-on-Cost % is ranked worse than 66.25% of 323
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs OSL:GENT: 1.51
Gentian Diagnostics AS (OSL:GENT) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Gentian Diagnostics AS 5-Year Yield-on-Cost % Related Terms
OSL:GENT vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's 5-Year Yield-on-Cost % falls into.
Gentian Diagnostics AS 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Gentian Diagnostics AS (OSL:GENT) has a 5-Year Yield-on-Cost % of 1.51 as of Jul. 28, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Gentian Diagnostics AS and its competitors. This is 104% above median its historical median of 0.74. Over the past decade, Gentian Diagnostics AS's 5-Year Yield-on-Cost % has ranged from 0.63 to 1.62. According to the industry distribution chart, Gentian Diagnostics AS ranks #214 out of 323 companies in the Medical Devices & Instruments industry, placing it in the top 66.3%.
Is Gentian Diagnostics AS's 5-Year Yield-on-Cost % too high?
Gentian Diagnostics AS's current 5-Year Yield-on-Cost % of 1.51 is 104% above median its 10-year median of 0.74. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 1.62. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.51. Gentian Diagnostics AS's value of 1.51 is 39.8% below this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #214 out of 323 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gentian Diagnostics AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #214 out of 323 companies for 5-Year Yield-on-Cost %. This places Gentian Diagnostics AS in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.51. Gentian Diagnostics AS's value of 1.51 is 39.8% below this benchmark. Historically, Gentian Diagnostics AS's own 5-Year Yield-on-Cost % has ranged from 0.63 to 1.62 over the past decade. While the company's 10-year median is 0.74 vs. the industry median of 2.51, Gentian Diagnostics AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.51, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current 5-Year Yield-on-Cost % of 1.51 is 39.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current 5-Year Yield-on-Cost % is 1.51, which is 104% above median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.21, compared to a current price of kr39.80 — trading 32.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.51, which is 104% above median its 10-year median of 0.74 and 39.8% below the Medical Devices & Instruments industry median of 2.51. Gentian Diagnostics AS's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current 5-Year Yield-on-Cost % is 1.51 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr39.80 is trading 32.8% below its estimated GF Value™ of kr59.21.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
5-Year Yield-on-Cost %: 1.51 (104% above median its 10-year median of 0.74)
GF Value™: kr59.21 vs. price of kr39.80 (32.8% below fair value)
Industry Position: 39.8% below the Medical Devices & Instruments median (#214 of 323)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
77GF Score
Get the complete analysis for OSL:GENT
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
